Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$1.95
-7.1%
$3.10
$1.91
$5.64
$129.73M1.291.42 million shs2.73 million shs
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
$11.05
+0.5%
$11.19
$4.11
$28.68
$137.35M2.6963,951 shs59,219 shs
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
$2.73
-9.6%
$5.38
$1.25
$145.46
$31.70M2.67863,697 shs426,029 shs
Zura Bio Limited stock logo
ZURA
Zura Bio
$2.02
-1.0%
$1.54
$0.97
$5.07
$131.34M-0.02508,232 shs160,363 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
0.00%-4.98%-20.45%-40.17%-9.09%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
0.00%-2.74%+14.46%+15.18%+39.24%
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
0.00%-10.39%-68.54%-1.31%+754,900.00%
Zura Bio Limited stock logo
ZURA
Zura Bio
0.00%-0.49%+36.00%+90.65%-50.61%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2.6505 of 5 stars
3.43.00.00.02.71.70.6
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
3.4467 of 5 stars
3.55.00.00.03.31.70.6
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
Zura Bio Limited stock logo
ZURA
Zura Bio
3.1727 of 5 stars
3.53.00.00.02.53.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2.83
Moderate Buy$10.10417.95% Upside
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
3.00
Buy$68.00515.38% Upside
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
0.00
N/AN/AN/A
Zura Bio Limited stock logo
ZURA
Zura Bio
3.00
Buy$14.00593.07% Upside

Current Analyst Ratings Breakdown

Latest PPCB, FBRX, CRDF, and ZURA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/19/2025
Zura Bio Limited stock logo
ZURA
Zura Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$3.00 ➝ $2.00
8/18/2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$75.00
8/18/2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$75.00
8/15/2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$61.00
8/15/2025
Zura Bio Limited stock logo
ZURA
Zura Bio
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$17.00 ➝ $16.00
8/15/2025
Zura Bio Limited stock logo
ZURA
Zura Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
8/6/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$18.00 ➝ $10.00
7/8/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$19.00
6/24/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$3.50
6/24/2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$61.00
6/18/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$680K190.78N/AN/A$1.86 per share1.05
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/A$8.21 per shareN/A
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
N/AN/AN/AN/A($493.34) per shareN/A
Zura Bio Limited stock logo
ZURA
Zura Bio
N/AN/AN/AN/A$2.27 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$45.43M-$0.87N/AN/AN/A-9,344.14%-77.94%-63.65%11/6/2025 (Estimated)
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$35.48M-$16.29N/AN/AN/AN/A-85.38%-72.34%11/13/2025 (Estimated)
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
-$1.82MN/A0.00N/AN/A-3,652.66%-971.09%N/A
Zura Bio Limited stock logo
ZURA
Zura Bio
-$45.39M-$0.70N/AN/AN/AN/A-49.11%-40.06%11/6/2025 (Estimated)

Latest PPCB, FBRX, CRDF, and ZURA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$1.21-$0.96+$0.25-$0.96N/AN/A
8/14/2025Q2 2025
Zura Bio Limited stock logo
ZURA
Zura Bio
-$0.19-$0.17+$0.02-$0.17N/AN/A
7/29/2025Q2 2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$0.19-$0.21-$0.02-$0.21$0.11 million$0.12 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/AN/AN/AN/AN/A
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/AN/A
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
N/AN/AN/AN/AN/A
Zura Bio Limited stock logo
ZURA
Zura Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/A
4.42
4.42
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/A
11.74
11.74
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
0.01
2.24
2.24
Zura Bio Limited stock logo
ZURA
Zura Bio
N/A
8.40
8.40

Institutional Ownership

CompanyInstitutional Ownership
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
16.29%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
77.63%
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
N/A
Zura Bio Limited stock logo
ZURA
Zura Bio
61.14%

Insider Ownership

CompanyInsider Ownership
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
7.70%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
5.90%
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
0.10%
Zura Bio Limited stock logo
ZURA
Zura Bio
22.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2066.53 million61.40 millionOptionable
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
512.43 million11.70 millionOptionable
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
111.61 million19,000Not Optionable
Zura Bio Limited stock logo
ZURA
Zura Bio
365.02 million50.65 millionOptionable

Recent News About These Companies

FY2025 EPS Estimates for Zura Bio Lifted by HC Wainwright
Zura Bio (NASDAQ:ZURA) Shares Up 7.5% - What's Next?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cardiff Oncology stock logo

Cardiff Oncology NASDAQ:CRDF

$1.95 -0.15 (-7.14%)
Closing price 04:00 PM Eastern
Extended Trading
$1.96 +0.02 (+0.77%)
As of 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Forte Biosciences stock logo

Forte Biosciences NASDAQ:FBRX

$11.05 +0.05 (+0.45%)
Closing price 04:00 PM Eastern
Extended Trading
$11.04 -0.01 (-0.05%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Propanc Biopharma stock logo

Propanc Biopharma OTCMKTS:PPCB

$2.73 -0.29 (-9.60%)
As of 04:00 PM Eastern

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

Zura Bio stock logo

Zura Bio NASDAQ:ZURA

$2.02 -0.02 (-0.98%)
Closing price 04:00 PM Eastern
Extended Trading
$2.04 +0.02 (+0.99%)
As of 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.